English: Thank you, Deputy Presiding Officer. I welcome the opportunity to update Members on the introduction of pre-exposure prophylaxis, which we'll now refer to as 'PrEP', one year after it's introduction here in Wales. PrEP, as you know, is an antiretroviral medication, which, if taken correctly, can prevent HIV for those at risk. Public Health Wales undertook work with an independent HIV expert group in November 2016 to assess the public health effectiveness of PrEP. A health technology assessment of this treatment was also undertaken by the All Wales Medicines Strategy Group in April 2017. On 28 April 2017, I announced my decision to provide the drug Truvada as PrEP to all those who would benefit from this preventative treatment as apart of an all-Wales study. That study will last up to three years. It started in July 2017 and it will provide evidence for the acceptability and the effectiveness of PrEP in HIV prevention. Public Health Wales and the independent HIV expert group are overseeing this study, and health boards in Wales began providing PrEP in July last year through integrated sexual health clinics. Sexual health services have worked hard to introduce this intervention and I am pleased to say that all integrated sexual health clinics in Wales have been providing PrEP from the outset. Any patient for whom PrEP is deemed suitable is required to have a negative HIV test and a baseline blood test to ensure they have no underlying health conditions. They are also required to receive counselling before PrEP is provided. Between 1 July 2017 and 30 June 2018, 989 patients in Wales were deemed eligible for PrEP. Almost half of these individuals were new or relatively new to sexual health services. It is important that individuals who participate in high-risk sexual behaviour engage with our sexual health services both to protect themselves and others. And making PrEP available has encouraged this. I can confirm that at least five individuals have been diagnosed with HIV as a result of their engagement with sexual health services for PrEP. These individuals can now receive the care that they need to stay well. A total of 559 people started on PrEP during the first year of this study and I am very pleased to say that no new cases of HIV have been diagnosed within this group of people. However, services did diagnose a number of significant sexually transmitted infections within this group. There were 70 cases of gonorrhoea and 15 cases of syphilis. That is to be expected in a high-risk group. What is important now is that they are attending sexual health services regularly, being diagnosed early and being treated for both their own health gain as well as preventing the spread of those infections to others. Members may have seen coverage of a story over the summer recess about the Terrence Higgins Trust having to fundraise to make PrEP treatment available. I want to reassure Members and the wider public that this problem relates to England and not to Wales. I have decided to take a national approach to PrEP and HIV prevention here in Wales in direct contrast to England, where a national approach is not being taken and a charity is looking to raise funds for PrEP treatment. Our latest figures show a 32 per cent decrease in new HIV cases in Wales, returning to 2011 levels. As important as PrEP is - and there is no doubt that PrEP reduces HIV infection - it is one part of the wider strategy to reduce new infections of HIV. PrEP needs to be taken correctly and supported by wider, preventative sexual health services. I look forward to updating you on further progress regarding our targeted efforts to reduce the transmission of HIV here in Wales. I will of course keep Members updated on the PrEP study and the planned wider improvements to our sexual health services.
Welsh: Diolch, Dirprwy Lywydd. Rwy'n croesawu'r cyfle i roi'r wybodaeth ddiweddaraf i'r Aelodau ar gyflwyno proffylacsis cyn-gysylltiad, y byddwn bellach yn cyfeirio ato fel 'PrEP', flwyddyn ar ôl ei gyflwyno yma yng Nghymru. Mae PrEP, fel y gwyddoch chi, yn feddyginiaeth gwrth-retrofeirysol, a all, os caiff ei gymryd yn gywir, atal HIV ar gyfer y rhai sydd mewn perygl o'i gael. Bu Iechyd Cyhoeddus Cymru yn gweithio gyda grŵp annibynnol o arbenigwyr HIV ym mis Tachwedd 2016 i asesu effeithiolrwydd iechyd cyhoeddus PrEP. Cynhaliwyd asesiad technoleg iechyd o'r driniaeth hon hefyd gan Grŵp Strategaeth Feddyginiaethau Cymru Gyfan ym mis Ebrill 2017. Ar 28 Ebrill 2017, cyhoeddais fy mhenderfyniad i ddarparu cyffuriau Truvada fel PrEP i bawb a fyddai yn elwa o'r driniaeth ataliol hon yn rhan o astudiaeth Cymru gyfan. Bydd yr astudiaeth honno yn para hyd at dair blynedd. Dechreuodd ym mis Gorffennaf 2017 a bydd yn darparu tystiolaeth ar gyfer pa mor dderbyniol ac effeithiol yw PrEP yn atal HIV. Mae Iechyd Cyhoeddus Cymru a'r grŵp HIV arbenigol annibynnol yn goruchwylio'r astudiaeth hon, a dechreuodd byrddau iechyd yng Nghymru ddarparu PrEP ym mis Gorffennaf y llynedd drwy glinigau iechyd rhywiol integredig. Mae gwasanaethau iechyd rhywiol wedi gweithio'n galed i gyflwyno'r ymyriad hwn ac rwy'n falch o ddweud bod yr holl glinigau iechyd rhywiol integredig yng Nghymru wedi bod yn darparu PrEP o'r cychwyn cyntaf. Mae angen i unrhyw glaf y bernir bod PrEP yn addas ar ei gyfer gael prawf HIV negyddol a phrawf gwaed sylfaenol i sicrhau nad oes ganddyn nhw unrhyw gyflyrau iechyd sylfaenol. Mae hefyd yn ofynnol iddyn nhw dderbyn cwnsela cyn y darperir PrEP. Rhwng 1 Gorffennaf 2017 a 30 Mehefin 2018, barnwyd bod 989 o gleifion yng Nghymru yn gymwys i gael PrEP. Roedd bron i hanner yr unigolion hyn yn newydd neu yn gymharol newydd i wasanaethau iechyd rhywiol. Mae'n bwysig bod unigolion sy'n cymryd rhan mewn arferion rhywiol peryglus yn ymwneud â gwasanaethau iechyd rhywiol i ddiogelu eu hunain ac eraill. Ac mae rhoi PrEP ar gael wedi annog hyn. Gallaf gadarnhau bod o leiaf pum unigolyn wedi cael diagnosis o HIV o ganlyniad i'w hymgysylltu â gwasanaethau iechyd rhywiol ar gyfer PrEP. Gall yr unigolion hyn bellach gael y gofal sydd ei angen arnynt i gadw'n iach. Mae cyfanswm o 559 o bobl wedi dechrau ar PrEP yn ystod blwyddyn gyntaf yr astudiaeth hon ac rwy'n falch iawn o ddweud nad oes unrhyw achosion newydd o HIV wedi bod o fewn y grŵp hwn o bobl. Fodd bynnag, roedd gwasanaethau wedi rhoi diagnosis ar gyfer nifer sylweddol o heintiau a drosglwyddir yn rhywiol yn y grŵp hwn. Roedd 70 achos o gonorea a 15 achos o siffilis. Mae hynny i'w ddisgwyl mewn grŵp risg uchel. Yr hyn sy'n bwysig yn awr yw eu bod yn mynychu gwasanaethau iechyd rhywiol yn rheolaidd, yn cael diagnosis cynnar ac yn cael eu trin ar gyfer adfer eu hiechyd eu hunain yn ogystal ag atal lledaenu'r heintiau hynny i eraill. Efallai fod Aelodau wedi gweld darllediadau o'r stori dros doriad yr haf am Ymddiriedolaeth Terrence Higgins i godi arian i sicrhau bod triniaeth PrEP ar gael. Rwyf eisiau sicrhau Aelodau a'r cyhoedd ehangach bod y broblem hon yn berthnasol i Loegr ac nid i Gymru. Rwyf wedi penderfynu mabwysiadu dull cenedlaethol o ran PrEP ac atal HIV yma yng Nghymru mewn cyferbyniad uniongyrchol â Lloegr, lle nad oes dull gweithredu cenedlaethol a ble mae elusen yn ceisio codi arian ar gyfer triniaeth PrEP. Mae ein ffigurau diweddaraf yn dangos gostyngiad o 32 y cant mewn achosion newydd o HIV yng Nghymru, gyda'r ffigyrau'n dychwelyd i lefelau 2011. Er pwysiced yw PrEp - ac nid oes unrhyw amheuaeth bod PrEP yn lleihau haint HIV - mae'n un rhan o'r strategaeth ehangach i leihau heintiau newydd o HIV. Mae angen i PrEP gael ei gymryd yn gywir a'i gefnogi gan wasanaethau iechyd rhywiol ehangach, ataliol. Edrychaf ymlaen at roi'r wybodaeth ddiweddaraf i chi ar gynnydd pellach ynghylch ein hymdrechion penodol i leihau trosglwyddo HIV yma yng Nghymru. Byddaf wrth gwrs yn rhoi'r wybodaeth ddiweddaraf i aelodau am yr astudiaeth PrEP a'r gwelliannau ehangach a gynlluniwyd i'n gwasanaethau iechyd rhywiol.